Guard Therapeutics International (OM:GUARD) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

GUARD Panoramica delle azioni

Guard Therapeutics International AB (publ), azienda farmaceutica, identifica, sviluppa e commercializza terapie per la diagnosi e il trattamento delle lesioni renali acute in Svezia.

Informazioni sull'azienda

GUARD analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	1/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( SEK0 )

Si prevede che gli utili diminuiranno in media di 6.3% all'anno per i prossimi 3 anni

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Non ha una capitalizzazione di mercato significativa ( SEK342M )

+ 1 più rischio

Guard Therapeutics International AB (publ) Concorrenti

Curasight

NGM:CURAS

DKK 243.0m

SynAct Pharma

OM:SYNACT

SEK 342.8m

Medivir

OM:MVIR

SEK 344.4m

Abliva

OM:ABLI

SEK 302.4m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Guard Therapeutics International
Prezzi storici delle azioni
Prezzo attuale dell'azione	SEK 28.80
Massimo di 52 settimane	SEK 49.80
Minimo di 52 settimane	SEK 6.78
Beta	-0.076
1Variazione di 1 mese	1.41%
Variazione a 3 mesi	-19.10%
Variazione di 1 anno	271.61%
3Variazione a 3 anni	-69.13%
Variazione a 5 anni	-63.31%
Variazione dall'IPO	-99.69%

Notizie e aggiornamenti recenti

Recent updates

Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky

Apr 18

Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely

Jan 04

Here's Why Guard Therapeutics International (STO:GUARD) Must Use Its Cash Wisely

Sep 20

Guard Therapeutics International (STO:GUARD) Is In A Good Position To Deliver On Growth Plans

Apr 06

We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Sep 09

Here's Why We're A Bit Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Feb 19

We're Not Very Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Aug 17

Companies Like Guard Therapeutics International (STO:GUARD) Are In A Position To Invest In Growth

Apr 19

Here's Why We're Watching Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Jan 04

Rendimenti per gli azionisti

	GUARD	SE Biotechs	SE Mercato
7D	1.4%	1.3%	-0.2%
1Y	271.6%	27.8%	18.4%

Ritorno vs Industria: GUARD ha superato il Swedish Biotechs che ha restituito 25.7 % nell'ultimo anno.

Rendimento vs Mercato: GUARD ha superato il mercato Swedish che ha restituito 21.3 % nell'ultimo anno.

Volatilità dei prezzi

Is GUARD's price volatile compared to industry and market?
GUARD volatility
GUARD Average Weekly Movement	7.0%
Biotechs Industry Average Movement	8.7%
Market Average Movement	5.6%
10% most volatile stocks in SE Market	12.2%
10% least volatile stocks in SE Market	3.3%

Prezzo delle azioni stabile: Il prezzo delle azioni di GUARD è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di GUARD è diminuita da 35% a 8% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2008	11	Tobias Agervald	guardtherapeutics.com

Guard Therapeutics International AB (publ), azienda farmaceutica, identifica, sviluppa e commercializza terapie per la diagnosi e il trattamento delle lesioni renali acute in Svezia. Offre ROSGard, un candidato farmaco biologico che previene il danno renale proteggendo, pulendo e riparando le cellule e i tessuti esposti. L'azienda, precedentemente nota come A1M Pharma AB (publ), ha cambiato nome in Guard Therapeutics International AB (publ) nell'ottobre 2019.

Guard Therapeutics International AB (publ) Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Guard Therapeutics International con la sua capitalizzazione di mercato?
GUARD statistiche fondamentali
Capitalizzazione di mercato	SEK 347.21m
Guadagni(TTM)	-SEK 78.82m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-4.4x

Rapporto P/E

GUARD è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
GUARD Conto economico (TTM)
Ricavi	SEK 0
Costo del fatturato	SEK 0
Profitto lordo	SEK 0
Altre spese	SEK 78.82m
Guadagni	-SEK 78.82m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-6.54
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato GUARD nel lungo periodo?

Vedi performance storica e confronto

GUARD Panoramica delle azioni

Premi

Analisi del rischio

Guard Therapeutics International AB (publ) Concorrenti

NGM:CURAS

DKK 243.0m

OM:SYNACT

SEK 342.8m

OM:MVIR

SEK 344.4m

OM:ABLI

SEK 302.4m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER

New major risk - Financial position

Guard Therapeutics Receives Regulatory EU Approvals to Include Patients in its Phase 2b Study POInter

New minor risk - Shareholder dilution

New major risk - Share price stability

New major risk - Revenue and earnings growth

Recent updates

First Patient Dosed in Guard Therapeutics' Phase 2B Study POINTER

New major risk - Financial position

Guard Therapeutics Receives Regulatory EU Approvals to Include Patients in its Phase 2b Study POInter

New minor risk - Shareholder dilution

New major risk - Share price stability

New major risk - Revenue and earnings growth

Companies Like Guard Therapeutics International (STO:GUARD) Could Be Quite Risky

No longer forecast to breakeven

New major risk - Share price stability

New major risk - Financial position

Guard Therapeutics International (STO:GUARD) Will Have To Spend Its Cash Wisely

New major risk - Revenue and earnings growth

Guard Therapeutics Reports Robust Efficacy of RMC-035 in Phase 2 (Akita) and Advances Clinical Development Program

Here's Why Guard Therapeutics International (STO:GUARD) Must Use Its Cash Wisely

New minor risk - Financial position

New major risk - Revenue and earnings growth

Guard Therapeutics International AB Announces Completion of Clinical Phase 2 Study AKITA

Guard Therapeutics Announces the Full Results from the Phase 1B Clinical Study of the Investigational Drug RMC-035 in Patients Undergoing Kidney Transplantation

Price target decreased by 36% to kr1.61

No longer forecast to breakeven

Price target decreased by 36% to kr1.61

Guard Therapeutics International (STO:GUARD) Is In A Good Position To Deliver On Growth Plans

No longer forecast to breakeven

Guard Therapeutics Announces First Patient in US Dosed with Study Drug in the Ongoing Global Phase 2 Clinical Trial AKITA

Guard Therapeutics International AB (Publ) Announces 134 of the Planned 268 Patients Have Been Dosed in the Global Randomized, Double-Blinded and Placebo-Controlled Phase 2 Clinical Trial

No longer forecast to breakeven

Guard Therapeutics International AB (publ) Receives FDA Fast Track Designation for RMC-035

Guard Therapeutics International AB (publ) Receives IND Approval from the FDA for RMC-035

We're Keeping An Eye On Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Guard Therapeutics Announces That the First Patient Has Been Dosed in A Phase 1b Clinical Trial of the Investigational Drug RMC-035 (ROSgard) in Kidney Transplantation

Guard Therapeutics Announces That the First Patient Has Been Dosed in A Phase 1b Clinical Trial of the Investigational Drug RMC-035 (ROSgard) in Kidney Transplantation

Guard Therapeutics Receives Approval from the Swedish Medical Products Agency to Conduct A Clinical Study of RMC-035 in Kidney Transplantation

Price target decreased to kr2.15

High number of new and inexperienced directors

Guard Therapeutics International AB (publ) Appoints Torbjörn Larsson as Head of CMC (Chemistry, Manufacturing and Controls), Effective 1 May 2022

Guard Therapeutics International AB (publ) Provides In-Depth Information on Phase 2 Clinical Trial

Guard Therapeutics Announces First Patient Has Been Dosed in Guard Therapeutics' Phase 2 Clinical Trial of ROSgard

Forecast to breakeven in 2024

Here's Why We're A Bit Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Chief Executive Officer recently bought kr1.6m worth of stock

Guard Therapeutics Receives Approval to Expand the Global Phase 2 Study of Rosgard to Canada

Guard Therapeutics’ Application to Conduct a Phase 2 Clinical Trial of ROSgard is Approved by the German Medicines Regulator

Chief Executive Officer recently bought kr300k worth of stock

Guard Therapeutics International AB (Publ) Reports Positive Results from Preclinical Studies

We're Not Very Worried About Guard Therapeutics International's (STO:GUARD) Cash Burn Rate

Companies Like Guard Therapeutics International (STO:GUARD) Are In A Position To Invest In Growth

Guard Therapeutics appoints Sara Thuresson as Head of Clinical Operations

New 90-day high: kr1.50

Here's Why We're Watching Guard Therapeutics International's (STO:GUARD) Cash Burn Situation

Guard Therapeutics International AB (Publ) Completes Pre-IND meeting with FDA

Guard Therapeutics Appoints Ann-Kristin Myde as Head of Global Project Management, Effective 1 April 2021

New 90-day low: kr1.22

New 90-day low: kr1.23

Guard Therapeutics Reports Positive Top-Line Results from Phase 1 Study of Rosgard in Individuals with Renal Impairment

New 90-day high - kr1.60

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Guard Therapeutics International AB (publ) Riepilogo dei fondamenti